Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 (ESTHER-1)
A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme
Sponsor: Ferring Pharmaceuticals
Listed as NCT01956110, this PHASE3 trial focuses on Infertility and remains completed. Sponsored by Ferring Pharmaceuticals, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2018 — Dec 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ferring Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brussels, Belgium , Burnaby, Canada , Copenhagen, Denmark , Glasgow, United Kingdom , Lille, France , Milan, Italy , Moscow, Russia , Ottawa, Canada , Porto Alegre, Brazil , Prague, Czechia and 3 more locations